Clinical completed trials


MEsenchymal StEm Cells for Multiple Sclerosis  (MESEMS)

This study will evaluate the safety of injecting MSCs in people with multiple sclerosis. The proposed therapeutic strategy is to modulate or suppress the aggressive immune process, to protect axons and neurons from degeneration, and to enhance repair and facilitate remyelination. 

Clinical indication

Multiple sclerosis

Disease area

Neurology

Cell type

ASC

Autologous/allogeneic

Autologous

Route of administration

Local

Biomaterial

Yes

Transgene

No

Activation/differentiation

No

Trial phase

1/2

Recruitment target

12

Year trial started

2015

Trial status

Completed

Clinical trial ID

NCT02403947

Website

-

   

Principal investigator : Michel Clanet (Toulouse UNiversity Hospital)

ECELLFrance activity : Cell production (ATMP)

ECELLFrance contact : Olivier Detante


Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing (Ortho-1)

The expected results are to obtain bone consolidation thus healing of delayed union or non-union using proposed IMP based on pluripotent MSCs expanded in a GMP facility and mixed with granulated biphasic calcium phosphate in the surgical setting before implantation.

Clinical indication

Delayed-union or non-union fractures of long bones

Disease area

Musculoskeletal

Cell type

BMSC

Autologous/allogeneic

Autologous

Route of administration

Local

Biomaterial

Yes

Transgene

No

Activation/differentiation

No

Trial phase

2

Recruitment target

30

Year trial started

2013

Trial status

Completed

Clinical trial ID

NCT01842477

Website

-

   

Principal investigator : Enrique Gomez-Barrena (Universidad Autonoma de Madrid)

ECELLFrance activities : Cell production (ATMP), gene modification/transfection, cell potency/QC, patient immunomonitoring, coordination (Luc Sensebé)

ECELLFrance contact : Hélène Rouard


Intravenous stem cell therapy for ischemic stroke (ISIS)

The main objective of the study is to evaluate feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells for patients presenting an ischemic stroke.

Clinical indication

Stroke

Disease area

Neurology

Cell type

BMSC

Autologous/allogeneic

Autologous

Route of administration

Systemic

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

2b

Recruitment target

31

Year trial started

2012

Trial status

Completed

Clinical trial ID

NCT00875654

Website

-

   

Principal investigator : Olivier Detante (ECELLFrance)

ECELLFrance activities : Cell production (ATMP), coordination (Olivier Detante)

ECELLFrance contact : Olivier Detante


ADIPOSE CELL DERIVED REGENRATIVE ENDOTHELIAL ANGIOGENIC MEDICINE (ACELLDREAM)

The main purpose of this study is to evaluate the efficacy of regenerative therapy with expanded adipose derived stromal/stem cells, administered intramuscularly in patients with critical leg ischemia.

Clinical indication

Critical limb ischemia

Disease area

Cardiology/Vascular

Cell type

ASC

Autologous/allogeneic

Autologous

Route of administration

Intramuscular 

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

Phase 1/2

Recruitment target

18

Year trial started

2017

Trial status

Completed

Clinical trial ID

NCT01211028

Website

-

   

Principal investigator : Jérome Roncalli (Toulouse University hospital, France)

ECELLFrance activities : cell production (ATMP), cell potency/QC

ECELLFrance contact :  Louis Casteilla


AUTOLOGOUS ADIPOSE-DERIVED MESENCHYMAL STROMAL CELLS (ASC) IN THE TREATMENT OF MILD TO MODERATE OSTEOARTHRITIS (ADIPOA)

To evaluate the safety of a single injection of autologous adipose derived mesenchymal stromal cells in the treatment of severe osteoarthritis of the knee joint (ADIPOA).

This study is designed to determine the safety and efficacy of a single injection of autologous adipose derived mesenchymal stromal cells (ASCs) on patients with severe osteoarthritis of the knee (OA)

Clinical indication

Osteoarthritis

Disease area

Musculoskeletal

Cell type

ASC

Autologous/allogeneic

Autologous

Route of administration

Local

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

1/2

Recruitment target

18

Year trial started

2012

Trial status

Completed

Clinical trial ID

NCT01585857

Website

-

   

Principal investigator : Christian Jorgensen (ECELLFrance)

ECELLFrance activities : Cell production (ATMP), coordination (Christian Jorgensen)

ECELLFrance contact : Christian Jorgensen


Mesenchymal Stem Cells and Myocardial Ischemia (MESAMI)

This study purpose is to evaluate the safety of injecting MSCs directly into the heart to repair and restore heart function in people who have had a heart attack and who have chronic myocardial ischemia with heart failure.

Clinical indication

Chronic Myocardial Ischemia

Disease area

Cardiology/Vascular

Cell type

BMSC

Autologous/allogeneic

Autologous

Route of administration

Local

Biomaterial

No

Transgene

No

Activation/differentiation

No

Trial phase

1/2

Recruitment target

10

Year trial started

2009

Trial status

Completed

Clinical trial ID

NCT01076920

Website

-

   

Principal investigator : Jérome Roncalli (Toulouse University hospital, France)

ECELLFrance activity : Cell production (ATMP)

ECELLFrance contact : Louis Casteilla